Havana, June 1 (Prensa Latina) Cuban President Miguel Díaz-Canel today highlighted success of using the drug HeberFeron in reducing by eight times the frequency of basal cell carcinoma, a type of skin cancer.
New successes of Cuban biotechnology and pharmaceutical industry founded by the historical leader Fidel Castro, the president wrote in his Twitter account in reference to an article on the subject published in local newspaper Granma.
The Caribbean statesman highlighted the favorable results of the medicine produced by the Center for Genetic Engineering and Biotechnology (CIGB), a reference in this type of research.
The publication reflects in its edition of this Saturday that the HeberFeron heals and reduces skin tumors of any size and avoids complex surgeries on the face, among other achievements.
The drug has an effective action on this type of advanced, locally extensive or invasive tumor in areas of high frequency such as the nose, ears, eyelids and facial areas around the eye, the article points out.
The Heberferon, considered another of the flagship products of the CIGB, is used in about 50 institutions in the Caribbean country, according to official sources. It is based on a combination of alpha and gamma interferons for the effective treatment of basal cell carcinomas, the most frequent and high incidence skin tumors in the world.